Evidence map›Paper›PMID 40414856›Full record

ArticleBMC cancer2025

Discovery of homocamptothecin derivative TOP-0618 as a radiosensitive agent for the treatment of pancreatic cancer.

Yin Tang, Chengyi Huang, Di Chen, Yangyang Gong, Liang Chen, Wenjuan Chen, Liang You, Zhenyuan Miao, Huojun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yin Tang *Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China.
Chengyi Huang *Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China.
Di Chen *Department of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China.
Yangyang GongDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China.
Liang ChenDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China.
Wenjuan ChenDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China.
Liang YouSchool of Pharmacy, Naval Medical University, Shanghai, 200433, China.
Zhenyuan MiaoSchool of Pharmacy, Naval Medical University, Shanghai, 200433, China. miaozhenyuan@hotmail.com.
Huojun ZhangDepartment of Radiation Oncology, Changhai Hospital affiliated to Naval Medical University, Shanghai, 200433, China. chyyzhj@163.com.

Funding

National Natural Science Foundation of China 82173743National Natural Science Foundation of China 82272742Shanghai Health Commission Leading Talent Program 2022LJ019
6 · The paper itself

Abstract

backgroundPancreatic cancer is one of the most lethal malignancies characterized by a complex tumor microenvironment (TME) and highly heterogeneous nature, making it resistant to radiotherapy. This study aims to evaluate the radiosensitizing effect of homocamptothecin derivative TOP-0618 on pancreatic cancer.

methodsClonogenic assays and cell viability assays were used to evaluate the radiosensitizing effects of TOP-0618 on pancreatic cancer cells. Cell cycle and apoptosis were detected using flow cytometry. A pancreatic bi-flank xenograft tumor model was used to evaluate the radiosensitivity of TOP-0618. H&E staining analyses and TUNEL staining were used to examine necrosis and apoptosis of pancreatic xenograft tumors.

resultsCytotoxicity assays revealed that IC

conclusionsOur work demonstrates the radiosensitizing effect of homocamptothecin derivative TOP-0618 on pancreatic cancer both in vivo and vitro, and lays a foundation for clinical transformation.

Indexed as

CamptothecinPancreatic NeoplasmsRadiation-Sensitizing AgentsAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalHumansMiceRadiation ToleranceXenograft Model Antitumor AssaysCamptothecinRadiation-Sensitizing AgentsHomocamptothecin derivativePancreatic cancerRadiosensitivityTOP-0618

Identifiers

PMID40414856
PMCPMC12103773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.